[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628477":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":32,"locations":38,"responsibleParty":199,"collaborators":31,"id":201,"slug":202,"hasResults":203,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":31,"eligibilityCriteria":207,"healthyVolunteers":203,"sex":208,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":31,"studyType":214,"phases":215,"briefSummary":218,"conditions":219,"keywords":31,"overallStatus":41,"whyStopped":31,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},{"fullName":5,"class":6},"RemeGen Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Group 1","EXPERIMENTAL","Drug: RC148 （Dose1） in combination with CAPEOX",[13],"Drug: RC148 (Dose 1) plus Capecitabine and Oxaliplatin",{"label":15,"type":10,"description":16,"interventionNames":17},"Experimental Group 2","Drug: RC148 RC148 (Dose 2) in combination with CAPEOX",[18],"Drug: RC148 (Dose 2) plus Capecitabine and Oxaliplatin",[20,26],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","RC148 (Dose 1) plus Capecitabine and Oxaliplatin",[9],[25],"RC148 (Dose 1) plus CAPEOX",{"type":21,"name":27,"description":27,"armGroupLabels":28,"otherNames":29},"RC148 (Dose 2) plus Capecitabine and Oxaliplatin",[15],[30],"RC148 (Dose 2) plus CAPEOX",null,[33],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Hongfang Li","CONTACT","010-65018841","hongfang.li@remegen.com",[39,52,57,66,75,84,88,97,106,115,120,128,136,145,154,163,172,181,190],{"facility":40,"status":41,"city":42,"state":43,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":31},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},{"facility":53,"status":41,"city":42,"state":43,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":54,"geoPoint":56,"contacts":31},"Beijing Friendship Hospital, Capital Medical University",{"type":47,"coordinates":55},[49,50],{"lat":50,"lon":49},{"facility":58,"status":41,"city":59,"state":60,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":61,"geoPoint":65,"contacts":31},"Chongqing University Cancer Hospital","Chongqing","Chongqing Municipality",{"type":47,"coordinates":62},[63,64],106.55771,29.56026,{"lat":64,"lon":63},{"facility":67,"status":41,"city":68,"state":69,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":70,"geoPoint":74,"contacts":31},"Fujian Medical University Union Hospital","Fuzhou","Fujian",{"type":47,"coordinates":71},[72,73],119.30611,26.06139,{"lat":73,"lon":72},{"facility":76,"status":41,"city":77,"state":78,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":79,"geoPoint":83,"contacts":31},"Meizhou People's Hospital","Meizhou","Guangdong",{"type":47,"coordinates":80},[81,82],116.11768,24.28859,{"lat":82,"lon":81},{"facility":85,"status":41,"city":86,"state":87,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":31,"geoPoint":31,"contacts":31},"Guangxi Medical University Cancer Hospital","Nanjing","Guangxi",{"facility":89,"status":41,"city":90,"state":91,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":92,"geoPoint":96,"contacts":31},"The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital","Shijiazhuang","Hebei",{"type":47,"coordinates":93},[94,95],114.47861,38.04139,{"lat":95,"lon":94},{"facility":98,"status":41,"city":99,"state":100,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":101,"geoPoint":105,"contacts":31},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan",{"type":47,"coordinates":102},[103,104],113.64861,34.75778,{"lat":104,"lon":103},{"facility":107,"status":41,"city":108,"state":109,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":110,"geoPoint":114,"contacts":31},"Tongji Medical College of Huazhong University of Science &Technology","Wuhan","Hubei",{"type":47,"coordinates":111},[112,113],114.26667,30.58333,{"lat":113,"lon":112},{"facility":116,"status":41,"city":108,"state":109,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":117,"geoPoint":119,"contacts":31},"Union Hospital Tongji Medical College Huazhong University of Science and Technology",{"type":47,"coordinates":118},[112,113],{"lat":113,"lon":112},{"facility":121,"status":41,"city":86,"state":122,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":123,"geoPoint":127,"contacts":31},"Jiangsu Cancer Hospital","Jiangsu",{"type":47,"coordinates":124},[125,126],118.77778,32.06167,{"lat":126,"lon":125},{"facility":129,"status":41,"city":130,"state":122,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":131,"geoPoint":135,"contacts":31},"Affiliated Hospital of Jiangnan University","Wuxi",{"type":47,"coordinates":132},[133,134],120.28857,31.56887,{"lat":134,"lon":133},{"facility":137,"status":41,"city":138,"state":139,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":140,"geoPoint":144,"contacts":31},"The first hospital of Jilin University","Changchun","Jilin",{"type":47,"coordinates":141},[142,143],125.32278,43.88,{"lat":143,"lon":142},{"facility":146,"status":41,"city":147,"state":148,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":149,"geoPoint":153,"contacts":31},"Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality",{"type":47,"coordinates":150},[151,152],121.45806,31.22222,{"lat":152,"lon":151},{"facility":155,"status":41,"city":156,"state":157,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":158,"geoPoint":162,"contacts":31},"Shanxi Cancer Hospital","Taiyuan","Shanxi",{"type":47,"coordinates":159},[160,161],112.56028,37.86944,{"lat":161,"lon":160},{"facility":164,"status":41,"city":165,"state":166,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":167,"geoPoint":171,"contacts":31},"West China Hospital of Sichuan University","Chengdu","Sichuan",{"type":47,"coordinates":168},[169,170],104.06667,30.66667,{"lat":170,"lon":169},{"facility":173,"status":41,"city":174,"state":175,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":176,"geoPoint":180,"contacts":31},"People's Hospital of Tianjin","Tianjin","Tianjin Municipality",{"type":47,"coordinates":177},[178,179],117.17667,39.14222,{"lat":179,"lon":178},{"facility":182,"status":41,"city":183,"state":184,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":185,"geoPoint":189,"contacts":31},"Yunnan Cancer Hospital","Kunming","Yunnan",{"type":47,"coordinates":186},[187,188],102.71833,25.03889,{"lat":188,"lon":187},{"facility":191,"status":41,"city":192,"state":193,"zip":31,"country":44,"countryCode":45,"cosmosGeoPoint":194,"geoPoint":198,"contacts":31},"The Second Affiliated Hospital Zhejiang University School of Medicine","Hangzhou","Zhejiang",{"type":47,"coordinates":195},[196,197],120.16142,30.29365,{"lat":197,"lon":196},{"type":200,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100628477","phase-2-a-phase--clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer-100628477",false,"NCT07462143","A Phase Ⅱ\u002FⅢ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","A Randomized, Multicenter, Phase Ⅱ\u002FⅢ Study of RC148 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy as First-line Treatment for Unresectable or Metastatic Colorectal Cancer","Inclusion Criteria:\n\n1. Voluntarily agree to participate in the study, sign the informed consent form, and be able to comply with the study protocol.\n2. Aged 18-75 years old (including 18 years old and 75 years old).\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n4. Expected survival period ≥ 12 weeks.\n5. At least one measurable lesion according to RECIST v1.1 criteria.\n6. Histologically or cytologically confirmed colorectal adenocarcinoma, judged by the investigator as unsuitable for curative treatment, and no prior systemic anti-tumor treatment in the recurrent or metastatic stage.\n7. Subjects must be able to provide tumor tissue samples for biomarker detection.\n8. Adequate bone marrow, liver, kidney, and coagulation function.\n9. Female subjects of childbearing potential must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must have a negative blood pregnancy test within 7 days before study enrollment; male subjects must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment.\n\nExclusion Criteria:\n\n1. Known to have microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR).\n2. Imaging shows obvious tumor necrosis or cavitation, and the investigator judges that participation in the study may increase the risk of bleeding.\n3. Subjects with brain metastases.\n4. Toxicities from prior anti-tumor therapy have not recovered to ≤ grade 1 according to NCI-CTCAE v6.0.\n5. Known hypersensitivity or delayed-type allergy to any component of the study drug or similar drugs.\n6. Subjects with refractory nausea and vomiting, chronic gastrointestinal diseases, or other diseases that may interfere the adequate absorption, distribution, metabolism, or excretion of oral drugs.\n7. Subjects with acute, chronic, or symptomatic infections.\n8. Subjects with diagnosed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severe impairment of lung function, or other lung diseases.\n9. Subjects with active inflammatory bowel disease, a history of gastrointestinal perforation and\u002For fistula, or clinical symptoms of gastrointestinal obstruction.\n10. Subjects with severe arterial\u002Fvenous thromboembolic events within 6 months before randomization.\n11. Active gastrointestinal bleeding, hemoptysis, peptic ulcer, or hemorrhagic events requiring intervention within 28 days before randomization; or presence of severe esophagogastric varices or epistaxis.\n12. Presence of symptomatic or intervention-requiring third-space effusions.\n13. Subjects with active or previously diagnosed autoimmune diseases that may recur.\n14. History of other invasive malignant tumors within 5 years before randomization, or presence of any residual evidence of previously diagnosed malignant tumors.\n15. Subjects who are pregnant, lactating, or planning to become pregnant.","ALL","18 Years","75 Years",{"count":212,"type":213},80,"ESTIMATED","INTERVENTIONAL",[216,217],"PHASE2","PHASE3","This is a Phase Ⅱ\u002FⅢ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)",[220],"Colorectal (Colon or Rectal) Cancer","2026-05-18",{"date":223,"type":224},"2026-05-22","ACTUAL",{"date":226,"type":224},"2026-05-12",{"date":228,"type":213},"2030-12-31",{"name":5,"class":6},19]